The Effect of Selective Estrogen Receptor Modulators on Type 2 Diabetes Onset in Women: Basic and Clinical Insights

Overview

Journal J Diabetes Complications

Specialty Endocrinology

Date 2017 Feb 11

PMID 28185712

Citations 10

Authors

Beibei Xu

Dragana Lovre

Franck Mauvais-Jarvis

Affiliations

Soon will be listed here.

Abstract

Selective estrogen receptor modulators (SERMs) are a class of compounds that interact with estrogen receptors (ERs) and exert agonist or antagonist effects on ERs in a tissue-specific manner. Tamoxifen, a first generation SERM, is used for treatment of ER positive breast cancer. Raloxifene, a second generation SERM, was used to prevent postmenopausal osteoporosis. The third-generation SERM bazedoxifene (BZA) effectively prevents osteoporosis while preventing estrogenic stimulation of breast and uterus. Notably, BZA combined with conjugated estrogens (CE) is a new menopausal treatment. The menopausal state predisposes to metabolic syndrome and type 2 diabetes, and therefore the effects of SERMs on metabolic homeostasis are gaining attention. Here, we summarize knowledge of SERMs' impacts on metabolic, homeostasis, obesity and diabetes in rodent models and postmenopausal women.

Citing Articles

An update on selective estrogen receptor modulator: repurposing and formulations.

Patel R, James V, Prajapati B Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39820645 DOI: 10.1007/s00210-024-03753-w.

Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy.

Thomas N, Scalzo R, Wellberg E Nat Rev Endocrinol. 2023; 20(1):16-26.

PMID: 37783846 PMC: 11487546. DOI: 10.1038/s41574-023-00899-0.

Influence of genistein and diadizine on regularity of estrous cycle in cyclic female Wistar rat: interaction with estradiol receptors and vascular endothelial growth factor.

Elsayed D, Helmy S, Dessouki A, El-Nahla A, Abdelrazek H, El-Hak H Open Vet J. 2023; 12(5):639-648.

PMID: 36589405 PMC: 9789761. DOI: 10.5455/OVJ.2022.v12.i5.8.

Treatment of Diabetes and Osteoporosis-A Reciprocal Risk?.

Zawada A, Ratajczak A, Rychter A, Szymczak-Tomczak A, Dobrowolska A, Krela-Kazmierczak I Biomedicines. 2022; 10(9).

PMID: 36140292 PMC: 9495959. DOI: 10.3390/biomedicines10092191.

Proteomics Profiling of Osteoporosis and Osteopenia Patients and Associated Network Analysis.

Al-Ansari M, Aleidi S, Masood A, Alnehmi E, Abdel Jabar M, AlMogren M Int J Mol Sci. 2022; 23(17).

PMID: 36077598 PMC: 9456664. DOI: 10.3390/ijms231710200.

References

Hozumi Y, Kawano M, Jordan V . In vitro study of the effect of raloxifene on lipid metabolism compared with tamoxifen. Eur J Endocrinol. 2000; 143(3):427-30. DOI: 10.1530/eje.0.1430427. View

Mu Y, She R, Zhang H, Dong B, Huang C, Lin W . Effects of estrogen and androgen deprivation on the progression of non-alcoholic steatohepatitis (NASH) in male Sprague-Dawley rats. Hepatol Res. 2009; 39(9):910-20. DOI: 10.1111/j.1872-034X.2009.00512.x. View

Van Pelt R, Gozansky W, Wolfe P, Kittelson J, Jankowski C, Schwartz R . Estrogen or raloxifene during postmenopausal weight loss: adiposity and cardiometabolic outcomes. Obesity (Silver Spring). 2013; 22(4):1024-31. PMC: 3968229. DOI: 10.1002/oby.20653. View

Tommaselli G, Carlo C, Nasti A, Giordano E, Pisano G, Pellicano M . Effects of bilateral ovariectomy and postoperative hormonal replacement therapy with 17beta-estradiol or raloxifene on serum leptin levels. Menopause. 2003; 10(2):160-4. DOI: 10.1097/00042192-200310020-00008. View

Stevenson J, Chines A, Pan K, Ryan K, Mirkin S . A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials. J Clin Endocrinol Metab. 2015; 100(6):2329-38. DOI: 10.1210/jc.2014-2649. View

Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J . Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295(23):2727-41. DOI: 10.1001/jama.295.23.joc60074. View

Liu C, Huang J, Cheng S, Chang Y, Lee J, Liu T . Fatty liver and transaminase changes with adjuvant tamoxifen therapy. Anticancer Drugs. 2006; 17(6):709-13. DOI: 10.1097/01.cad.0000215056.47695.92. View

Gunel N, Coskun U, Balos Toruner F, Sancak B, Yilmaz E, Cengiz O . Serum leptin levels are associated with tamoxifen-induced hepatic steatosis. Curr Med Res Opin. 2003; 19(1):47-50. DOI: 10.1185/030079902125001308. View

Velasco G, Geelen M, Guzman M . Control of hepatic fatty acid oxidation by 5'-AMP-activated protein kinase involves a malonyl-CoA-dependent and a malonyl-CoA-independent mechanism. Arch Biochem Biophys. 1997; 337(2):169-75. DOI: 10.1006/abbi.1996.9784. View

10.

Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant H . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282(7):637-45. DOI: 10.1001/jama.282.7.637. View

11.

Hozumi Y, Kawano M, Miyata M . Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocr J. 1998; 44(5):745-9. DOI: 10.1507/endocrj.44.745. View

12.

Carr M, Knopp R, Brunzell J, Wheeler B, Zhu X, Lakshmanan M . Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy. Diabetes Care. 2005; 28(7):1555-61. DOI: 10.2337/diacare.28.7.1555. View

13.

Kim Y, Lee S, Jung J, Kwon Y, Lee G, Shin D . Severe acute pancreatitis due to tamoxifen-induced hypertriglyceridemia with diabetes mellitus. Chin J Cancer Res. 2014; 26(3):341-4. PMC: 4076723. DOI: 10.3978/j.issn.1000-9604.2014.05.01. View

14.

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280(7):605-13. DOI: 10.1001/jama.280.7.605. View

15.

Considine R, Sinha M, Heiman M, Kriauciunas A, STEPHENS T, Nyce M . Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334(5):292-5. DOI: 10.1056/NEJM199602013340503. View

16.

Cagnacci A, Paoletti A, Zanni A, Arangino S, Ibba G, Orru M . Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women. J Clin Endocrinol Metab. 2002; 87(9):4117-21. DOI: 10.1210/jc.2002-020120. View

17.

Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S . Tamoxifen-induced fatty liver in patients with breast cancer. Lancet. 1998; 351(9104):725. DOI: 10.1016/S0140-6736(05)78493-2. View

18.

Villa A, Della Torre S, Stell A, Cook J, Brown M, Maggi A . Tetradian oscillation of estrogen receptor α is necessary to prevent liver lipid deposition. Proc Natl Acad Sci U S A. 2012; 109(29):11806-11. PMC: 3406808. DOI: 10.1073/pnas.1205797109. View

19.

Badman M, Pissios P, Kennedy A, Koukos G, Flier J, Maratos-Flier E . Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007; 5(6):426-37. DOI: 10.1016/j.cmet.2007.05.002. View

20.

Barrera J, Chambliss K, Ahmed M, Tanigaki K, Thompson B, McDonald J . Bazedoxifene and conjugated estrogen prevent diet-induced obesity, hepatic steatosis, and type 2 diabetes in mice without impacting the reproductive tract. Am J Physiol Endocrinol Metab. 2014; 307(3):E345-54. DOI: 10.1152/ajpendo.00653.2013. View